Caius G. Radu

Caius G. Radu

Auto-generated profile, based on publicly available information

Caius G. Radu

Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in International Immunology
Verified
Journal Article
Open access
PDF file
RORaimund J. Ober
Raimund J. Ober
CRCaius G. Radu
Caius G. Radu
VGVictor Ghetie
Victor Ghetie
EWE. Sally Ward
E. Sally Ward
Preclinical tests of therapeutic antibodies are frequently carried out in mice to evaluate pharmacokinetics and efficacy. However, the observation that mouse IgG are cleared rapidly from the human circulation suggests that mice may not always be an ideal model. The Fc receptor, FcRn, regulates the serum half-lives of IgG in mice and most likely has a similar function in humans. In the current study we have carried out an extensive analysis of the interaction of the human or mouse forms of FcRn with IgG from various species using surface plasmon resonance. We show that in contrast to mouse FcRn, human FcRn is surprisingly stringent in its binding specificity for IgG derived from different species. Human FcRn binds to human, rabbit and guinea pig IgG, but not significantly to rat, bovine, sheep or mouse IgG (with the exception of weak binding to mouse IgG2b). In contrast, mouse FcRn binds to all IgG analyzed. The lack of binding of human FcRn to mouse IgG1 has been confirmed using transfectants that have been engineered to express human FcRn on the cell surface. Our results provide a molecular explanation for the enigmatic observation that mouse IgG behave anomalously in humans. These studies have implications for the successful application of therapeutic antibodies.

22 May 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CMChao Ma
Chao Ma
RFRong Fan
Rong Fan
HAHabib Ahmad
Habib Ahmad
QSQihui Shi
Qihui Shi
BCBegonya Comin-Anduix
Begonya Comin-Anduix
JHJames R Heath
James R Heath

6 December 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies. Significance: Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247

1 August 2001 in International Immunology
Verified
Journal Article
Open access
PDF file
MFMihail Firan
Mihail Firan
RBRoger Bawdon
Roger Bawdon
CRCaius Radu
Caius Radu
RORaimund J. Ober
Raimund J. Ober
DEDarla Eaken
Darla Eaken
EWE. Sally Ward
E. Sally Ward
The transfer of maternal γ-globulin (IgG) provides the neonate with humoral immunity during early life. In humans, maternal IgG is transported across the placenta during the third trimester of pregnancy. The expression of the MHC class I-related receptor, FcRn, in the human placenta suggests that this Fc receptor might be involved in the delivery of maternal IgG, but direct evidence to support this is lacking. In the current study an ex vivo placental model has been used to analyze the maternofetal transfer of a recombinant, humanized (IgG1) antibody in which His435 has been mutated to alanine (H435A). In vitro binding studies using surface plasmon resonance indicate that the mutation ablates binding of the antibody to recombinant mouse and human FcRn. Relative to the wild-type antibody, the H435A mutant is deficient in transfer across the placenta. Significantly, the mutation does not affect binding to FcγRIII, an FcR that has been suggested in earlier studies to mediate the transfer of maternal IgG. The analyses demonstrate that binding of an IgG to FcRn is a prerequisite for transport across the perfused placenta. FcRn therefore plays a central role in the maternofetal delivery of IgG and this has implications for the use of protein engineering to improve the properties of therapeutic antibodies.

30 January 2007 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RBRyan C. Bailey
Ryan C. Bailey
GKGabriel A. Kwong
Gabriel A. Kwong
CRCaius G. Radu
Caius G. Radu
OWOwen N. Witte
Owen N. Witte
JHJames R. Heath
James R. Heath

30 April 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TCThinle Chodon
Thinle Chodon
BCBegoña Comin-Anduix
Begoña Comin-Anduix
BCBartosz Chmielowski
Bartosz Chmielowski
RKRichard C. Koya
Richard C. Koya
ZWZhongqi Wu
Zhongqi Wu
ARAntoni Ribas
Antoni Ribas
Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination. We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy. Experimental Design: A clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation. Results: A total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1–specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1–specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells. Conclusion: Double cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses. Clin Cancer Res; 20(9); 2457–65. ©2014 AACR.